浙江拱东医疗器械股份有限公司 2022 年第三季度报告 证券代码：605369 证券简称：拱东医疗 浙江拱东医疗器械股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | 单位：万元 | 币种：人民币 | | --- | --- | --- | --- | --- | | | | 本报告期比 | | 年初至报告 | | 项目 | 本报告期 | 上年同期增 | 年初至报告 | 期末比上年 | | | | 减变动幅度 | 期末 | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 38,068.54 | 40.63 | 117,965.26 | 39.32 | | 归属于上市公司股东的净利润 | 9,789.96 | 30.72 | 30,844.87 | 22.42 | | 归属于上市公司 ...

Financial Performance - The company's operating revenue for 2021 was CNY 119,425.42 million, representing a 43.95% increase compared to CNY 82,965.18 million in 2020[22]. - The net profit attributable to shareholders for 2021 was CNY 31,098.72 million, a 37.68% increase from CNY 22,588.10 million in 2020[22]. - The net cash flow from operating activities reached CNY 37,298.62 million, up 54.01% from CNY 24,218.25 million in 2020[22]. - The total assets at the end of 2021 were CNY 168,991.12 million, a 22.84% increase from CNY 137,567.83 million at the end of 2020[22]. - The basic earnings per share for 2021 was CNY 2.77, an increase of 11.24% compared to CNY 2.49 in 2020[24]. - The weighted average return on equity for 2021 was 24.66%, a decrease of 9.46 percentage points from 34.12% in 2020[24]. - The company achieved a revenue of 1,194.25 million RMB in 2021, representing a growth of 43.95% compared to the previous year[63]. - The net profit attributable to shareholders reached 310.99 million RMB, an increase of 37.68% year-on-year[63]. - The total assets amounted to 1,689.91 million RMB, with a debt total of 301.88 million RMB, resulting in an asset-liability ratio of 17.86%[63]. Dividend Distribution - The company plans to distribute a cash dividend of 13.80 RMB per 10 shares, totaling approximately 155.43 million RMB, which accounts for 49.98% of the net profit attributable to shareholders[6]. - The company’s total share capital is 112,627,120 shares as of the dividend distribution proposal date[6]. Audit and Compliance - The company reported a standard unqualified audit opinion from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[5]. - The company has not experienced any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures regarding external guarantees[8]. - The company emphasizes transparency in investor relations and adheres to strict information disclosure obligations[178]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[177]. - The company has not faced any significant legal or regulatory discrepancies in its governance practices[179]. Market and Sales Performance - Domestic sales revenue reached RMB 770.35 million, a significant increase of 85.30% compared to 2020[42]. - The overseas sales revenue was RMB 418.06 million, showing a modest growth of 3.54% year-on-year[42]. - The company’s main products include vacuum blood collection systems, laboratory testing consumables, and medical care consumables, which are widely used in clinical diagnostics and care[51]. - The marketing network covers over 100 countries and regions, with established partnerships with international clients such as McKesson and Thermo Fisher[58]. - The company’s investment activities saw an increase in cash outflow due to higher spending on financial products and fixed asset purchases[68]. Research and Development - Research and development expenses totaled RMB 58.29 million, accounting for 4.88% of the total revenue, with a year-on-year increase of 57.62%[40]. - The company obtained 11 new utility model patents and 1 design patent during the reporting period[40]. - The company has been recognized as a high-tech enterprise, emphasizing its commitment to research and technological innovation[51]. - The strategic focus for R&D includes the development of customized products and high-precision mold manufacturing processes to support future projects[110]. Operational Efficiency - The company has restructured its domestic sales operations into three independent departments: "Medical Business," "IVD Supporting Business," and "Pharmaceutical Business" to enhance management efficiency[43]. - The company employs a "make-to-order" production model to optimize inventory management and reduce storage costs[52]. - The company is currently operating at full capacity and will implement various measures to expand production capacity, including the construction of an intelligent factory[159]. - The company will improve its management system and organizational model to meet the growing demands of its expanding asset and production scale[161]. Risks and Challenges - The company has outlined potential risks in its future development, which investors should be aware of[9]. - Future fluctuations in raw material prices, influenced by global commodity prices, could adversely affect the company's operating performance if not managed properly[171]. - The implementation of centralized procurement policies may pose risks to the company, particularly if it cannot adapt to changes in the low-value medical consumables sector[169]. Governance and Management - The company has established specialized committees, including Audit, Nomination, Compensation and Assessment, and Strategic Decision Committees, to enhance governance[197]. - The company is committed to maintaining effective oversight of financial reporting and auditing processes through its committees[198]. - The company has a history of management changes, with several key personnel having extensive experience in the medical device industry[188]. - The company reported significant management stability, with many executives having long tenures in their respective roles[188]. Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22]. - The company aims to become a world-leading supplier of disposable medical consumables, focusing on high quality and efficiency[157]. - In 2022, the company plans to enhance production capacity and accelerate new product development, while exploring applications of polymer consumables in life sciences and veterinary fields[158]. - The company intends to utilize investment and acquisition strategies to seek global cooperation opportunities and optimize its industrial layout[166].

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 浙江拱东医疗器械股份有限公司 2022 年第一季度报告 证券代码：605369 证券简称：拱东医疗 浙江拱东医疗器械股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：万元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年同期 | | --- | --- | --- | --- | | | | | 增减变动幅度(%) | | 营业收入 | | 34,774.92 | 32.71 | | 归属于上市公司股东的净利润 | | 9,505.43 | 19.77 | | 归属于上市公司股东的扣除非经常 | | 9,2 ...

浙江拱东医疗器械股份有限公司 2021 年第三季度报告 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 （一）主要会计数据和财务指标 证券代码：605369 证券简称：拱东医疗 浙江拱东医疗器械股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 单位：万元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | 年初至报告期 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 动幅度(%) | 末 | 增减变动幅度 | | | | | | (%) | | 营业收入 | 27,069.64 | 7.62 | 84,673.66 ...

浙江拱东医疗器械股份有限公司 2021 年半年度报告 公司代码：605369 公司简称：拱东医疗 浙江拱东医疗器械股份有限公司 2021 年半年度报告 1 / 165 浙江拱东医疗器械股份有限公司 2021 年半年度报告 重要提示 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的经营计划、发展战略、未来计划等前瞻性陈述不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间 的差异。 七、 是否存在被控股股东及其关联方非经营性占用资金情况？ 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性？ 否 十、 重大风险提示 公司已在本报告中描述可能存在的相关风险，敬请投资者予以关注并查阅本报告第三节"管 理层讨论与分析"之五"其他披露事项"中（一）"可能面对的风险"以及本报告第十节"财务 报告"之十"与金融工具相关的风险"之相关内容。 十一、 其他 □适用 √不适用 2 / 165 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实 ...

Financial Performance - Operating income reached CNY 26,203.50 million, a year-on-year increase of 155.93%[5] - Net profit attributable to shareholders was CNY 7,936.30 million, up 232.18% year-on-year[5] - The basic earnings per share increased by 147.50% to CNY 0.99[5] - The company's operating revenue for Q1 2021 reached RMB 26,203.50 million, a significant increase of 155.93% compared to RMB 10,238.41 million in the same period last year[15] - The company's profit before tax saw a substantial rise, leading to income tax expenses of RMB 1,294.30 million, up 408.21% from RMB 254.68 million in the previous year[16] - Operating profit for Q1 2021 was ¥92,407,444.53, up from ¥26,740,319.71 in Q1 2020, representing a growth of 245.5%[29] - Net profit for Q1 2021 was ¥79,363,027.05, compared to ¥23,891,296.23 in Q1 2020, marking an increase of 231.5%[30] - The total profit for Q1 2021 was ¥92,306,044.77, compared to ¥26,438,092.74 in Q1 2020, an increase of 249.5%[29] Cash Flow - Net cash flow from operating activities surged by 477.67% to CNY 7,496.84 million[5] - The net cash flow from operating activities for Q1 2021 was ¥74,968,444.93, up from ¥12,977,822.01 in Q1 2020, representing a growth of 478%[35] - The cash inflow from operating activities totaled ¥291,695,126.78 in Q1 2021, compared to ¥117,729,264.36 in Q1 2020, reflecting a growth of 147%[35] - The company reported a net increase in cash and cash equivalents of ¥30,515,315.59 in Q1 2021, contrasting with a decrease of -¥69,425,330.57 in Q1 2020[36] Assets and Liabilities - Total assets increased by 8.63% to CNY 149,436.63 million compared to the end of the previous year[5] - The total liabilities increased significantly, with contract liabilities rising by 91.38% to RMB 5,858.98 million due to increased sales[14] - Current liabilities rose to CNY 346,887,237.31, compared to CNY 163,324,507.84 in the previous period, indicating a significant increase of about 112.5%[21] - The total liabilities increased to CNY 350,964,243.26 from CNY 167,737,235.03, reflecting a growth of approximately 109.0%[21] - The total assets as of March 31, 2021, amounted to RMB 1,141,863,175.16, compared to RMB 1,047,376,755.51 at the end of 2020[19] Shareholder Information - The number of shareholders reached 11,843 at the end of the reporting period[11] - The top shareholder, Shi Huiyong, holds 52.50% of the shares, totaling 42,000,000 shares[11] Research and Development - The company's R&D expenses increased by 140.48% to RMB 1,109.84 million, indicating a focus on innovation and product development[15] - Research and development expenses in Q1 2021 amounted to ¥11,098,409.42, which is 140.5% higher than ¥4,615,119.03 in Q1 2020[31] Inventory and Accounts Receivable - Inventory rose by 44.67% to RMB 9,712.33 million, driven by the increase in sales volume[14] - Accounts receivable financing increased by 54.45% to RMB 1,443.87 million, attributed to increased sales and more bank acceptance bills received[14] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[13]

浙江拱东医疗器械股份有限公司 2020 年年度报告 公司代码：605369 公司简称：拱东医疗 浙江拱东医疗器械股份有限公司 2020 年年度报告 1/207 浙江拱东医疗器械股份有限公司 2020 年年度报告 重要提示 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人施慧勇、主管会计工作负责人潘磊及会计机构负责人（会计主管人员）程菊文声 明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2020年度利润分配预案为： 1、公司拟向全体股东每10股派发现金红利18.00元（含税）。截至2020年12月31日，公司总 股本8,000.00万股，以此计算合计拟派发现金红利14,400.00万元（含税），占合并报表中归属于母 公司股东净利润的63.75%，剩余未分配利润结转至下一年度。 2、公司拟向全体股东以资本公积金转增股本方式每10股转增4股。截至2020年12月31日，公 司总股本8,000.00万股，本次转股后，公司的总股本为11,200.00万股。 3、如在本利润分配预案披露之日起至实施权益分派股权 ...

| 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 浙江拱东医疗器械股份有限公司 2020 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 浙江拱东医疗器械股份有限公司 2020 年第三季度报告 公司代码：605369 公司简称：拱东医疗 浙江拱东医疗器械股份有限公司 2020 年第三季度报告 1 / 26 3 / 26 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上 年度末增减(%) 总资产 1,281,682,286.09 536,041,068.14 139.10 归属于上市公司股东的净资产 1,141,707,336.77 405,248,147.50 181.73 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减 (%) 经营活动产生的现金流量净额 160,340,651.45 74,445,769.52 115.38 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年 ...